Portfolio company Eos SENOLYTIX agreed to merge with Nasdaq-listed Pulmatrix, with the combined company expected to trade publicly on Nasdaq.
Eos SENOLYTIX is a longevity company using MitoXcel™ Technology to develop novel therapeutics targeting the fundamental mechanisms of aging
Eos SENOLYTIX is a longevity company using MitoXcel™ Technology to develop novel therapeutics targeting the fundamental mechanisms of aging. Its lead clinical candidates, PTC-2105 and PTC-2107, are proprietary geropeptides that rejuvenate aged cells by improving mitochondrial function and eliminating senescent cells.